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 CHAPTER I 
 
INTRODUCTION TO INTERFEROMETRY 
 
Applications of Interferometry across the Disciplines 
When two or more light waves are superimposed, an interference pattern is 
created.  By studying these patterns, the properties of the light waves and of the material 
that they have been in contact with can be explored.  This field, known as interferometry, 
has led to the development of some of the most sensitive optical techniques available and 
has been applied to various applications, including astronomy, metrology, oceanography, 
seismology, and biological sciences.  
 Interferometry was first applied in the field of astronomy over two centuries ago 
to investigate why stars appear larger through a telescope relative to other objects.1  
Later, the technique was utilized to determine the actual diameter of various astronomical 
objects.2, 3  Today, astronomical interferometers have provided some of the highest 
resolution images of our galaxy.3  In the field of applied metrology, interferometry is an 
essential tool used to characterize optical components; for example, the technique may be 
used to detect deformations in mirror blanks or to inspect the quality of a lens or an 
optical fiber.4-6  In oceanography, interferometry has been used for imaging ocean surface 
features, such as currents and wave movements.7, 8  Seismology frequently utilizes 
interferometry to image the topography of the earth, and can be used to measure and 
study deformations caused by events such as earthquakes and explosions.9, 10 
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 Interferometric Biosensors 
Interferometry has also been applied to biological sciences as a tool to monitor 
and quantify molecular interactions.  Within this field, interferometry offers the dual 
advantage of being a highly sensitive technique that does not require the use of expensive 
molecular labels.  Therefore, molecular interactions may be characterized with both 
binding partners in their native states, eliciting quantitative, meaningful (i.e. unperturbed 
by labeling) affinity data in a cost-effective format.  Here we explore several different 
types of interferometers which have been successfully utilized to study molecular 
interactions. 
 
Mach-Zehnder interferometer 
The Mach-Zehnder interferometer (MZI) utilizes a waveguiding method to 
monitor the difference in refractive index (RI) between a sample and reference arm of the 
waveguide (Figure 1.1).  A laser illuminates a single-mode waveguide which is then split 
into a sample and reference arm.  The reference arm is coated with a thin cladding layer, 
while the sample arm has a window to allow the evanescent field to interact with the 
sample.  The sensor and reference arms are then recombined, leading to beam 
interference.  Any change in the sample’s refractive index produces a phase shift in the 
sensor arm beam, which in turn results in a change in the output intensity when the two 
beams are recombined.  Binding events are thereby measurable using photodetection.  
Intrinsically, the evanescent sensing approach of the MZI instrumental configuration 
requires a single polarization and single-mode illumination to prevent interference from 
cross-polarization and multimodal effects.  The sensitivity of the MZI is typically 
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 correlated with the length of the sensing window, making it difficult to measure low 
concentrations of analytes without using large amounts of sample.  
 
Light Source
Reference
Channel
Camera
Interaction Channel
 
Figure 1.1 Illustration of a Mach-Zehnder interferometer 
 
The MZI was first used for biosensing in 1993 and has since been utilized in a 
broad range of applications.11-15  In 1997, Brosinger et al. demonstrated the ability to 
resolve a refractive index change of 2 × 10−5 refractive index units (RIU) with their early 
MZI configuration.12  Initial experiments to test the biosensing ability of the instrument 
were also reported, demonstrating that MZI can detect fetal calf serum binding 
nonspecifically to the sensor surface.12  More recently, Prieto et al. used a Mach-Zehnder 
interferometer total internal reflection (MZI-TIR) configuration to achieve a minimum 
refractive index change of 7 × 10−6 at the sensor surface.  The utility of the instrument 
was demonstrated by detecting the interaction between a covalently immobilized 
pesticide and its antibody in PBST (phosphate buffered saline Tween).13  The same group 
also constructed an MZI based on a rib anti-resonant reflecting optical waveguide 
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 (ARROW).  The use of ARROW structures instead of conventional TIR waveguides 
allows for larger core and rib dimensions, making the instrument more compatible with 
mass-production and also lowering insertion losses.  However, these advantages are 
accompanied by a loss in sensitivity -- the minimum detectable refractive index change 
for the MZI-ARROW was found to be 2 × 10−5.14 
 
Young interferometer 
Another waveguiding interferometer is the Young interferometer (YI).  The YI 
configuration includes a single-mode laser illuminating a single-mode waveguide, which 
is then split into a sample and reference arm, as in the Mach-Zehnder interferometer.  
However, instead of the interference being created when the waveguides recombine as in 
the MZI, in a YI the optical output of the waveguides interact in free space to create the 
interference fringes, which are displayed onto a CCD camera (Figure 1.2).   
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Light Source
Interaction Channel
Reference Channel
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Figure 1.2 Illustration of a Young interferometer 
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 The YI was first used to measure molecular interactions in 199411 and has been 
widely published on thereafter.16-18  In 2003, Ymeti et al. showed that their multi-channel 
YI configuration can measure four different analyte concentrations simultaneously, 
achieving a refractive index resolution of 8.5 × 10−8 RIU.16  In 2006, Hradetzky et al. 
reported a refractive index detection limit of 0.9 × 10−6 for their single-cell YI, and 
detected the hybridization of 21-mer DNA with immobilized receptor DNA at the 
biosensor surface.17  Their findings suggested the detection limit of this DNA-DNA 
binding interaction to be in the picomolar range. 
 
Hartman interferometer 
 The Hartman interferometer (HI) is also a waveguiding technique; however, in 
contrast with the MZI and YI, this approach utilizes a planar waveguide that is patterned 
with lines of immobilized molecules (Figure 1.3).  Light is directed into the waveguide 
through a grating to create a single broad beam.  The light then passes through parallel 
sensing regions which are coated with different receptors to create distinct binding and 
control regions.  The light then travels though integrated optics that combine the light 
from neighboring regions to create interference.  The interference signals then pass 
through another grating and to the detector.  The phase shift of the interference patterns is 
measured to detect refractive index changes. 
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Figure 1.3 Illustration of a Hartman interferometer 
 
 In 1997, Schneider et al. demonstrated the broad applications of the HI as a real-
time detector of nucleic acid, protein, and pathogen analytes.  Experiments were 
performed by immobilizing the receptor (anti-hCG antibody) to the sensor surface, 
allowing for real-time detection of human chorionic gonadotropin (hCG) with a direct 
detection limit of 2 ng/mL in phosphate buffered saline (PBS).  DNA hybridization 
experiments detected a four-base mismatch in 50% formamide hybridization buffer, and a 
nucleic acid detection capability of 1011 copies per mL was achieved.19  In early 2000, the 
same group expanded on these applications, demonstrating the ability of their 
configuration to detect hCG in human serum at clinically relevant levels of 0.1 ng/mL.  
Extensive studies of the nonspecific binding associated with serum samples were also 
performed, which concluded that the HI can overcome this particular setback using a 
reference region and controlled surface chemistry.20  Later that year, Schneider et al. took 
their studies a step further by detecting hCG in whole blood; despite significantly higher 
background levels than buffer or serum systems, a clinically relevant detection limit of 
0.5 ng/mL hCG was achieved.21 
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Diffraction optics 
 Diffraction-based sensing employs a similar technique of immobilizing the probe 
molecules into a pattern that will diffract the incoming laser light to create an interference 
pattern (Figure 1.4).  This pattern has been shown to change as sample is introduced and 
binding occurs on the stripes of capture species, resulting in a change in the height and 
refractive index of the diffraction grating.  The intensity of the refractive spots is 
measured using a photodectector, allowing any changes within the sample to be 
measured.  While many applications of diffraction optics offer enhanced performance 
when used in conjunction with labeling strategies, the following examples focus 
primarily on label-free applications of the technique.  
 
Light Source
Patterned 
Substrate
Diffraction 
Image
 
Figure 1.4 Illustration of a biosensor based on diffraction optics 
 
 Early studies by St. John et al. demonstrated that diffraction optics can be used to 
detect whole bacteria cells captured using an antibody grating stamped on a silicon 
surface.22  In 2005, Goh et al. demonstrated the ability of diffraction optics to measure 
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 two different binding interactions simultaneously without the use of labels.  To achieve 
this, receptor molecules mouse IgG and rabbit IgG were immobilized in two different 
patterns via PDMS stamping on the same 2D surface.  Anti-mouse IgG and anti-rabbit 
IgG were then introduced into the cell sequentially.  The binding observed for each 
pattern indicated the specific binding of the target analyte exclusively to its receptor 
antibody.  These findings carry implications for diagnostic applications involving 
multiple markers and/or competition assays.23  Currently, Axela Biosensors offers a 
commercialized diffraction-based sensor known as the dotLab™ System which enables 
multiplexing of immunoassays over a broad dynamic range.  In 2007, they demonstrated 
the ability to simultaneously measure binding of two similar sets of antibody/analyte 
pairs with concentrations which differed by 6 orders of magnitude; however, labeling 
strategies were implemented to measure the analyte of lower concentration.24   
 
Dual polarization interferometer 
 The dual polarization interferometer (DPI) is another waveguide method for 
studying molecular interactions.  This technique utilizes two waveguides, a sample and 
reference waveguide, which are stacked together, so they may be illuminated by a single 
laser (Figure 1.5).  The light exiting the waveguides form an interference pattern in the 
farfield.  In contrast with other waveguide sensors, the polarization of the laser in the DPI 
is alternated so that two polarization modes of the waveguides are excited in succession 
in order to modulate the signal and increase sensitivity.  Using the information from the 
measurements of both polarization states, the refractive index and the thickness of the 
adsorbed protein layer can be calculated. 
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Figure 1.5 Illustration of a biosensor based on dual polarization interferometry 
 
 In 2003, Swann et al. measured the binding and surface loading of streptavidin to 
the biotin-functionlized surface of their DPI.  Nonspecific binding, thickness and density 
changes of protein layers as well as other structural aspects of the streptavidin-biotin 
system were also explored in detail using this tool.25  In 2006, Lin et al. used DPI to 
derive dissociation constants (KD) for homopolyvalent pentameric C-reactive protein 
(CRP) with monoclonal anti-CRP IgG; these values were in close agreement with those 
previously derived using enzyme-linked immunosorbent assays (ELISA).26  That same 
year, Ricard-Blum et al. measured the interaction of immobilized heparin with heparin 
binding protein HepV.  Exploring the stochiometric and kinetic parameters of this 
binding system using DPI lent insight into collagen V interaction with proteoglycans in 
tissues, a process which affects collagen fibril formation.27  In 2009, Wang et al. utilized 
DPI to measure the structural changes of electrostatically immobilized DNA upon 
binding to small molecules ethidium bromide and spermine in real time.  Changes in 
mass, thickness, and refractive index of the DNA sample layer (consisting of either native 
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 or denatured DNA) were monitored upon small molecule binding.  These studies 
harnessed the ability of DPI to measure structure and kinetics simultaneously and the 
flexibility of the technology to interrogate binding interactions over a large molecular 
size range.28  Farfield Sensors, Ltd has been commercializing DPI-based biosensing 
systems since 2000 with the introduction of the AnaLight® 250, and has most recently 
released the AnaLight® 4D which enables the measurement of structural changes within 
lipid bilayers.27, 29, 30 
 
Porous Si sensors 
 Porous silicon sensors have been developed using the principles of the Fabry-
Perot interferometer on thin films of porous silicon etched in a silicon substrate.  The 
porous Si film acts as the interferometer, creating fringes from reflections off the top and 
bottom of the pores (Figure 1.6).  As demonstrated by Sailor, et al. in 1999, this 
technique can overcome typical penetration depth limitations because the entire volume 
of the sample within the film is utilized for the measurement.31, 32  Limited penetration 
depth, or the inability to measure interactions which occur above the sensor surface, is a 
significant shortcoming present in other surface-based techniques.  
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Figure 1.6 Illustration of a Porous Si sensor 
 
 A 1997 Science paper by Lin, et al. reported the ability of a porous silicon-based 
optical interferometric bionsensor to detect the binding of small molecules, DNA 
oligomers, and proteins with unprecedented sensitivity (pico- and femtomolar 
concentrations).31  In 1999, Dancil et al. studied protein A and IgG binding via porous 
silicon biosensing.  This report highlighted the reversibility and stability of the system, as 
well as the ability to render the sensor insensitive to nonspecific binding.32  A 2003 
publication in Science by Li et al. demonstrated that porous silicon can serve as a 
template for the construction of complex optical structures (comprised of organic 
polymers or biopolymers, e.g.) in biosensor applications.  These more recent findings are 
of particular interest to drug delivery applications.33  
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 BioCD 
 The biological compact disk (BioCD) utilizes patterns of immobilized capture 
proteins on a disk with a mirrored surface to create periodic reflective interference 
spectra which are measurably altered by binding (Figure 1.7).34, 35  The interference 
signal is interrogated before and after the disk has been incubated with the sample, and 
the difference is correlated to the amount of binding that has occurred.  Unfortunately, 
because the BioCD discretely measures the relative difference in the reflectance patterns 
of surface immobilized proteins before and after binding, the tool is not readily applicable 
for real-time monitoring, rendering kinetics studies problematic.   
 
Gel-printed 
protein pattern
Light Source
Mirror
Lens
Detector
Bio CD
Beam 
expander
Spinner  
Figure 1.7 Illustration of a BioCD 
 
 Detection limits as low as 105 molecules has been achieved using the BioCD, 
which was employed to measure specific binding between anti-mouse IgG and mouse 
IgG using rabbit IgG as a control.34, 35  In an expanded effort, it was shown that binding 
12 
 measurements are concentration-dependent, illustrating the potential of the technique for 
quantitative analyses.36 In 2009, Wang et al. expanded applications of the technique 
further by employing the BioCD to perform multiplexed prostate specific antigen (PSA) 
detection in human serum.37  
 
Other reflective interferometric platforms 
 Recently, the principles of reflectance interferometry used in porous silicon and 
BioCD methods have been applied to other biosensor variations with increased 
multiplexing abilities.  In particular, Ozkumer et al. have introduced a multiplex platform 
known as the spectral reflectance imaging biosensor (SRIB) designed for high throughput 
use.  SRIB is based on the optical phase difference rendered by the binding of biological 
species to probes on a transparent layered surface.  This technique enables the collection 
of reflectance spectra for hundreds of spots on the array simultaneously.38, 39  Gauglitz et 
al. have used reflective interferometric spectroscopy (RIfS), a similar platform based on 
multiple white light reflections at thin transduction layers, to characterize biomolecule 
interactions in a multiplexed, high throughput format by attaching 96- and 384-well 
plates to the transducer slide.   The varied applications of this RIfS platform include use 
a screening tool for thrombin inhibitors and antibodies against triazine libraries.   
Biametrics is currently developing a commercial version of the RIfS platform.   
40
40, 41
42, 43
 
Backscattering interferometry 
A new technique, backscattering interferometry (BSI), was originally used to 
measure small refractive index changes in fused-silica capillaries.44 and has been 
developed in multiple configurations and for a wide array of applications.45-51  BSI has 
13 
 more recently been employed to study molecular interactions in a label-free method and 
has proven to be a versatile sensing technique; BSI can be used to investigate binding 
events in both a surface-immobilized scheme and in free solution.  This ability to 
measure interactions in a free-solution format makes BSI unique among interferometric 
techniques.  The free-solution advantage not only eliminates the time and monetary costs 
related to immobilization strategies, but also allows binding partners to be monitored 
entirely in their native state.  Furthermore, because BSI is dually amenable to both free-
solution and surface-immobilized formats, any contribution of immobilization to binding 
perturbation may be measured directly.  Perhaps surprising in light of the platform’s 
versatility is that BSI consists of an extremely simple optical train, requiring only a 
collimated coherent light source, a capillary or microfluidic chip (hemispherical or 
rectangular), and a detector.   
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Figure 1.8 Illustration of a backscattering interferometer 
 
 In the latest configuration of BSI, a microfluidic chip molded in 
polydimethylsulfoxide (PDMS) or etched in glass is employed.  BSI utilizes a red 
helium-neon (HeNe) laser (λ = 632.8 nm) to illuminate the microfluidic channel (Figure 
1.8).  While not absolutely necessary, the laser may be coupled to a collimating lens 
through a single-mode fiber.  When the laser beam impinges the channel and interacts 
with the fluid contained within the channel, a set of high contrast interference fringes is 
produced and monitored in the direct backscatter region at relatively shallow angles.  The 
spatial position of these fringes depends upon the refractive index (RI) of the fluid within 
the channel.  The change in fringe position is monitored using a CCD array in 
combination with Fourier analysis, enabling the quantification of the shift as a change in 
15 
 spatial phase, calculated in the Fourier domain.52  Molecular interaction studies 
performed in recent years using BSI technology will be detailed in Chapter II. 
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 CHAPTER II 
 
BACKSCATTERING INTERFEROMETRY AS A BIOSENSING TOOL 
 
Background and Significance 
Current label-free biosensing techniques for measuring protein interactions 
include surface plasmon resonance (SPR), calorimetric methods such as isothermal 
titration calorimetry (ITC), and interferometric methods such as backscattering 
interferometry (BSI).53  SPR measures refractive index changes near a gold surface to 
detect binding.  Although widely-used, SPR requires surface immobilization of targets 
and uses expensive gold-plated sensor chips of limited reusability.53-55  ITC measures 
reaction enthalpy to detect label-free binding events, but large sample volumes are 
typically required.  Furthermore, sensitivity is diminished by low or zero-value reaction 
enthalpies.56  As discussed in Chapter I, among the many interferometric biosensing 
techniques available, BSI is unique in its ability to interrogate label-free molecular 
interactions in either a heterogeneous (surface-immobilized) or a homogeneous (free-
solution) format at picomolar levels using picoliter volumes (corresponding to 10,000’s 
of molecules measured).56  Furthermore, in comparison with other label-free techniques 
such as SPR and ITC, BSI provides unmatched sensitivity and is the only tool that is fully 
compatible with microfluidics.53 
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Figure 2.1 Illustration of a binding event and the subsequent BSI signal produced. 
  
Heterogeneous Assays 
Originally BSI facilitated interaction assays in the heterogeneous mode, utilizing 
the immobilization of one binding partner onto the surface of a microfluidic chip molded 
in polydimethylsiloxane (PDMS).53, 54  In early experiments, streptavadin was 
immobilized onto the channel surface and the fringe pattern was measured before and 
after introducing biotin into the channel.  A good correlation was found between the BSI 
molecular interaction signal and the fluorescence signal reported in a similar experiment.  
Next, a biotinylated protein-A (PA) surface allowed the monitoring of reversible IgG-PA 
interactions with femtomole detection limits.35  New surface chemistry enabled a two-
fold improvement on detection limits of the protein A-IgG interaction without the use of 
a fluorescent label, and also allowed monitoring of the hybridization of complimentary 
18 
 strain of DNA at concentrations ranging from 5nM to 500 mM to a 30-mer of mActin.  
Assuming 100% surface coverage, the 3σ limit of quantification was found to be 36 
attomoles of DNA in the 500 pL detection volume.  Further experiments showed that a 3 
base pair mismatch could be detected, evidenced by a marked decrease in binding signal 
from that of the original complimentary strand – only 7 % of the signal generated by the 
binding of the complimentary strands was observed for the mismatched strand.54 
 The extraordinary sensitivity of BSI was further demonstrated by expanding on 
these preliminary observations to study lectin-sugar binding.57  Since BSI is not a film 
thickness sensor (i.e., signal is not dependent on a change in mass at the sensor surface), 
it was possible to measure the binding of concanavilin A (con A) to mannose and glucose 
and the binding of a lectin isolated from Griffonia simplicifolia (BS-1) to galactose.  
Biotinylated lectins (proteins) were attached in functional form to the surface of glass 
microfluidic channels coated with extravidin by simple mixing.58  The binding of 
unmodified carbohydrates was monitored by BSI and dose-response curves were used to 
generate values for association constants.  Mannose and glucose were found to bind to 
the lectin concanavalin A with dissociation constants of 42 ± 5 µM and 155 ± 88 µM, 
respectively; galactose bound to BS-1 lectin with a dissociation constant of 30.2 ± 2.8 
µM.57  This study is significant because it demonstrates that BSI uniquely allows 
quantification of a binding event for just one part in 1000 change in mass, allowing the 
protein to be tethered and the small molecule to be titrated.  To our knowledge this small 
molecule - protein assay has never been performed in this manner on another platform 
and represents a challenging assay for widely-used label-free techniques.   
19 
  In order to study multivalent interactions, the carbohydrate studies were then 
expanded to measure the binding of sugar-coated virus particles (cowpea mosaic virus 
(CPMV) and bacteriophage Qβ virus-like particles).57  CPMV particles with 
approximately 200 mannose molecules attached to the surface with three different linkers 
and were studied.  The binding of these virus particles to immobilized Con A was 
monitored and the saturation binding isotherms were plotted to determine the association 
constants.  Comparison of the affinity of the particles to that of free mannose showed an 
average of a 100-fold increase in affinity on a per-glycan basis.  Similarly, two different 
Qβ particles (450 and 470 mannose per particle) were studied, and the KD values showed 
an approximately 220 fold increase in affinity over that of free mannose on a per glycan 
basis.57  These studies illustrate that BSI has the potential to measure polymeric binding 
and the effects of cooperation.   
 
Free-Solution Assays 
 Likely the most novel aspect of BSI is that it can be used to measure free-solution 
molecular interactions.  Using a channel with a serpentine mixer and a restriction to mix 
the two interacting species on-chip, a stop-flow experiment can be performed label-free 
and in free solution to elicit real-time kinetic data.  Using these methods, systems 
reported were Protein A (PA) which binds with high affinity to the FC region of several 
immunoglobulin G (IgG) species, including human and rabbit; calmodulin (CaM), the 
ubiquitous calcium-binding protein that can bind to and regulate a multitude of different 
protein targets; and the interaction between IL-2 and a monoclonal antibody, in this case 
in buffer and in cell-free media.  Recent advancements of BSI have shown that molecular 
20 
 interaction assays can be performed utilizing exceedingly small amounts of sample at 
physiologically relevant concentrations, without the use of labels or surface 
immobilization, and in complex matrices.  For example, the entire CaM study (i.e., CaM-
Ca2+, CaM-TFP, CaM-M13 peptide, and CaM-calcineurin) required the consumption of 
only about 200 picomoles or 3 mg of CaM, and each binding event only required one 
minute for analysis.56 
 By quantifying the picomolar binding affinity of IL-2 in cell-free media,56 it was 
demonstrated that BSI has the potential to evaluate high-affinity interactions and is 
compatible with matrices more complex than buffer.  This unique ability to study free-
solution binding in complex matrices sets BSI apart. 
 Recently published results indicate that BSI can be used to screen structurally 
destabilized mutants of the T4 lysozyme (T4L) against the small heat-shock protein 
(sHSP) α-crystallin.59  sHSPs constitute a superfamily of molecular chaperone proteins, 
which help other proteins to fold properly to prevent aggregation.  Molecular chaperones 
have been linked to cataracts and neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s.59-61  In these experiments, the differential binding of chaperone proteins to 
T4L mutants of varying stabilities was quantified, demonstrating the remarkable 
specificity of BSI in characterizing binding interactions.59  
Although each of these examples were performed using a mixer chip to facilitate 
online mixing of reagents, it should be noted that solutions may also be pre-mixed off 
chip, enabling the determination of affinity measurements using an end-point format.56   
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 CHAPTER III 
 
BSI AND DIAGNOSTIC APPLICATIONS USING SYPHILIS AND HIV AS MODELS 
 
BSI as an Attractive Diagnostic Tool 
The ability of BSI to measure interactions rapidly using picoliter detection 
volumes in a free-solution format makes BSI unique among sensing techniques, 
eliminating time and monetary costs related to labeling and immobilization strategies.  
BSI will now be applied to disease-detection methods with the potential application as a 
reactive serum detector.  In collaboration with the Centers for Disease Control and 
Prevention (CDC) in Atlanta, GA, syphilis and human immunodeficiency virus (HIV) 
serology will be used as models for evaluating the diagnostic performance of BSI. 
 Current diagnostic tools rely heavily on signaling moieties to detect the presence 
of a particular antigen or antibody in a sample.  Such chemical labeling not only 
consumes time and resources, but may also alter the conformations and/or behavior of 
binding partners, obscuring test results.62  Introducing this variable necessitates that many 
common label-based diagnostic assays must be corroborated by additional testing 
methods, further increasing time, cost, and sample consumption.63  Diagnostics for 
diseases with a heavy worldwide presence and with marked prevalence in developing 
areas, such as syphilis and HIV, are particularly sensitive to time, cost, and sample 
volume considerations.  Therefore, a label-free microfluidic diagnostic tool has the 
potential to revolutionize point-of-care diagnostics for these and other widespread 
diseases. 
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 Of the available label-free techniques, BSI provides unmatched sensitivity and is 
the only tool that is fully compatible with microfluidics – critical advantages for 
diagnostic applications.56  BSI’s ability to detect antigen-antibody interactions has 
previously been established by the Bornhop group.56  In order to explore BSI’s capacity 
to detect syphilis and HIV infections in human sera, purified antigens will be used to 
detect antibodies in the sera raised against the infection.  Successful detection of syphilis 
and HIV infections in human specimens using BSI will not only provide innovative 
diagnostic approaches for these particular infections, but will serve as a benchmark in 
protein-based diagnostics, applicable to countless other diseases.  Using BSI to detect 
antigen-antibody interactions decreases cost, time, and sample volume considerations and 
may also offer the unique potential to quantify antibody levels in clinical samples.  Such 
an advantage may provide valuable information concerning disease status, severity, 
progression, and/or therapeutic efficacy. 
 
Syphilis Serology 
 
Background and Significance 
 Syphilis is a sexually-transmitted infectious disease caused by the bacterium 
Treponema pallidum for which no adequate in vitro culturing method has been 
developed.64, 65  Therefore, current syphilis diagnostic tests typically rely on the detection 
of anti-treponemal antibodies raised against the pathogen itself (i.e., treponemal tests) as 
well as nontreponemal tests for antibodies against lipoidal material released from 
damaged host cells and against lipoprotein-like secretions of the treponeme.64, 65  The 
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 most commonly used treponemal tests include the fluorescent treponemal antibody 
absorption (FTA-ABS) and the treponemal pallidum particle agglutination test (TP-PA), 
and current nontreponemal tests include the Venereal Disease Research Laboratory 
(VDRL) and the Rapid Plasma Reagin (RPR) tests.64, 65  While treponemal tests are 
highly specific, they give little or no indication of the status of the infection because anti-
treponemal antibodies are retained for a lifetime.  In contrast, nontreponemal tests are 
most reactive during active syphilis infection; when the disease is latent or has been 
effectively treated, the reactivity of the antiserum to these tests subsides.9  However, 
nontreponemal tests have shown a high rate of false-positive results (i.e., are relatively 
nonspecific) because anti-cardiolipin antibodies may be generated as a result of 
conditions unrelated to syphilis, including autoimmune diseases, tuberculosis, pregnancy, 
and vaccinations.66  Therefore, it is most informative to perform a treponemal and a 
nontreponemal diagnostic test in concert; a typical clinical diagnosis may be based upon 
an RPR or VDRL screening followed by a TP-PA or FTA-ABS confirmation.65    
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Figure 3.1 Illustration of TP-PA test well-plate.  Reactive (i.e. “positive”) samples spread 
across the bottom of the well as the serum antibodies agglutinate with the antigen-coated 
beads. 
 
Figure 3.2 Illustration of RPR test card. The reactivity of this sample would be 
characterized as “R4” due to inadequate antibody-antigen clumping of subsequent 
dilutions.  
 
Each of these diagnostic tests relies on a visual interpretation of results and/or 
labeling.  The FTA-ABS utilizes the reaction of fluorescently-labeled anti-IgG antibodies 
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 with anti-treponemal serum antibodies bound to an antigen-coated slide, detected using 
fluorescent microscopy.  The TP-PA test employs antigen-coated colored gelatin particles 
to visualize the hemagglutination of reactive antiserum (Figure 3.1).  The VDRL test 
evaluates the level of clumping between antiserum and a nontreponemal antigen 
containing cardiolipin, lecithin, and cholesterol as seen under a visisble light 
microscope.64, 65  The RPR test utilizes charcoal as a visualizing agent to detect this same 
clumping reaction with the naked eye (Figure 3.2).  The application of BSI to syphilis 
diagnostics would enable both treponemal and nontreponemal tests to be performed 
rapidly in a single low-volume assay format without the use of fluorescent tags, 
visualizing agents, or microscopy, decreasing time and cost considerations and increasing 
the quantitative potential of nontreponemal tests.  
 
Experimental procedures 
 Small aliquots from fractions number 2 – 6 of affinity-purified total IgG from a 
rabbit inoculated with the syphilis-causing bacterium Treponema pallidum were obtained 
from the CDC.  Increasing concentrations of total IgG (using fraction #5) were prepared 
in phosphate buffered saline (PBS), and each concentration was mixed with either a 
recombinant treponemal antigen r17 (Genway Biotech, Inc.), a nontreponemal free 
cardiolipin antigen (Sigma-Aldrich), or PBS to serve as a calibration.  The final 
concentrations of the total IgG were 0 – 50 µg/mL and the final antigen concentration 
was held in excess at 100 µg/mL.  The BSI signal was measured for each sample, and the 
bulk contributions of IgG and antigen were subtracted from the binding measurements 
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 using the IgG calibration.  The remaining signal, representing the antigen-antibody 
binding, was plotted versus IgG concentration.    
 Serum-based experiments paralleling the treponemal syphilis binding assay in 
buffer were conducted using a nonreactive (negative control) commercial serum sample 
obtained from a TrepSure enzyme immuno assay kit (Phoenix Bio-Tech Corporation) 
mixed with the increasing concentrations of total IgG (prepared using fraction #4).  Each 
concentration was then mixed with either recombinant treponemal antigen r17 antigen or 
PBS.  The final mixtures contained a 1:40 dilution of serum and an r17 antigen 
concentration of 100 µg/mL with IgG concentrations ranging from 0 to 50 µg/mL.  The 
BSI signal was measured for each sample and the bulk contributions of IgG, serum, and 
r17 antigen were subtracted in order to obtain the signal created during the binding event.  
This signal was plotted versus total IgG concentration.  
 Clinical serum samples from human patients used for syphilis serology 
experiments were provided by the CDC, having been previously classified according to 
reactivity using the treponemal particle agglutination (TP-PA) test and the nontreponemal 
rapid plasma regain (RPR) test.  The serum samples were first diluted with PBS and were 
then mixed with either A) a recombinant treponemal antigen r17 (resulting in a final 
concentration of 5 ug/mL r17) or B) a micellar cardiolipin antigen (resulting in a final 
dilution of 1:800 micelle prep).  It should be noted that this micellar cardiolipin antigen is 
a synthetic antigen newly developed by the CDC to enhance the specificity of 
cardiolipin-based assays, and therefore precise concentration information was not 
available.  Binding measurements were performed on-site at the CDC using a commercial 
BSI instrument that, while possibly more sensitive, is also more prone to chip clogging 
27 
 than the configuration used in previous experiments; therefore, final serum dilutions were 
increased to 1:400.  The binding signal of the interaction was measured and plotted 
versus the serum classification.  
 
Results and Discussion 
 Results from BSI assays measuring syphilis antibody – antigen interactions in 
PBS are shown in Figure 3.3.  This data indicates that the binding of the total 
immunoglobulin G (IgG) from a syphilitic rabbit to both treponemal and nontreponemal 
antigens produces a BSI signal.  Furthermore, this signal correlates with the quantity of 
IgG in the sample, assuming that an excess of antigen (recognized only by specific anti-
treponemal IgG) is present.  It should be noted that because this IgG preparation consists 
of total IgG and is not limited to specific anti-treponemal IgG molecules, the IgG 
concentrations noted here are arbitrary in that the actual concentration of IgG potentially 
binding to the antigen in these samples is unknown.  Therefore no affinity information 
regarding the interaction may be extracted.   
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Figure 3.3 BSI signal resulting from the reaction of purified total IgG in buffer with A) 
100 ug/mL r17 antigen and B) 100 ug/mL free cardiolipin antigen.  Error bars represent 
the standard deviation of triplicate determinations.  
 
 The binding of the treponemal antigen with the IgG in the presence of human 
serum is shown in Figure 3.4.  These results indicate that this reaction (and presumably 
other antigen-antibody reactions) may be detected against the complex serum matrix.  
Notably, a significantly lower signal is observed for the binding of each IgG 
concentration in serum than for the corresponding measurement performed in buffer.  
This muted signal suggests that a lower number of specific binding interactions are being 
detected above the calibration signal.  This apparent decrease in specific binding 
interactions may be the result of nonspecific binding between serum proteins and IgG in 
both the calibration and the binding assays, lowering the effective IgG concentration in 
the assay.  Alternatively, because these two measurement were performed using different 
IgG fractions (though both from the same extraction collected from a single animal), the 
quantities of specific anti-r17 IgG may differ for corresponding total IgG concentrations. 
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Figure 3.4 BSI signal resulting from the reaction of total IgG with 100 ug/mL r17 in the 
presence of human serum.  Error bars represent the standard deviation of triplicate 
determinations.  
 
 
 To expand on these studies, preliminary experiments to explore the potential 
performance of BSI as a reactive serum detector were performed using clinical human 
serum samples from syphilitic and healthy individuals. The BSI signal indicating the 
binding interaction of treponemal r17 antigen with each of 20 human serum samples, pre-
classified according to syphilis infection status and RPR titer strength, is shown in Figure 
3.5(A).  Titer strength is determined according to the highest serum dilution which still 
displays adequate clumping in the presence of the antigen in the RPR test; higher 
dilutions imply higher reactivity.64  However, because the RPR test utilizes a 
nontreponemal cardiolipin antigen and measures the level of cardiolipin antibodies in the 
serum, an RPR titer may, but is not necessarily expected to, correlate with signals 
generated using a treponemal antigen.  Therefore, the element of interest for this 
nontreponemal assay is the separation of positive from negative samples and not their 
correlation with titer strength.  Indeed, Figure 3.5(B) shows a statistically significant 
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 separation (p=1x10-5) between BSI signals for positive and negative samples, 
demonstrating that a signal threshold may be established for determining the reactivity of 
unclassified samples.  These results show promise for the application of BSI as a reactive 
serum detector. 
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Figure 3.5 A) BSI signal resulting from the reaction of human serum samples (pre-
classified according to titer strength with regard to syphilis infection) with r17 antigen. B) 
Average of signals for positive and negative samples (error bars represent the standard 
deviation of 10 samples), showing a statistically relevant separation between positive and 
negative signals (*p=1x10-5).   
 
 Figure 3.6 shows the resultant BSI signal from the reaction of a micellar 
cardiolipin antigen with 20 human serum of various titer strengths, according to the 
syphilis RPR test.  Figure 3.6.A demonstrates a correlation between the RPR titer 
strength and the measured BSI signal for nearly every sample.  This result is expected 
since a nontreponemal cardiolipin antigen is used in both the BSI determinations and the 
RPR test (i.ei, both assays aim to quantify serum antibodies raised specifically against 
cardiolipin antigens).  Further studies would be necessary to determine the reasoning for 
the anomalous reading of R1-A, which gives a BSI signal markedly larger than the other 
two samples with R1 titer strength.   
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  Figure 3.6.B shows a statistically significant separation (p=5x10-6) between BSI 
signals for positive and negative samples.  These results demonstrate that that a signal 
threshold may be established for determining the reactivity of unclassified samples using 
a cardiolipin antigen, as was demonstrated with the treponemal antigen in figure 3.5.B.   
 Overall, the the assay results shown in Figures 3.5 and 3.6 not only reiterate the 
potential of BSI to be used not as a reactive serum detector, but also show that BSI may 
enable the quantification of antibody levels in patient samples.  Perhaps most 
importantly, the ability to achieve congruent BSI results using two markedly different 
antigen probes highlights the multiplexing possibilities of BSI to streamline diagnostic 
approaches. 
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Figure 3.6 A) BSI signal resulting from the binding of human serum samples (pre-
classified according to titer strength with regard to syphilis infection) with micellar 
cardiolipin antigen, showing a correlation between RPR titer strength and BSI signal.  B) 
Average of signals for positive and negative samples (error bars represent the standard 
deviation of 10 samples), showing a statistically relevant separation between positive and 
negative signals (p=5x10-6).   
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 HIV Serology 
 
Background and Significance 
Human immunodeficiency virus (HIV) is a retrovirus which causes acquired 
immunodeficiency syndrome (AIDS), a pandemic life-threatening disease that severely 
compromises the immune system of infected individuals.  Routine HIV diagnostics test 
for serum antibodies raised against HIV proteins using the enzyme-linked 
immunosorbant assay (ELISA).67-69   If a positive result is obtained with this initial 
screening, a second diagnostic test is typically performed using a different assay format, 
such as a Western blot or an immunofluorescence assay (IFA), to confirm the result.67, 69   
Each of these methods requires labeling strategies for the visualization of serum 
antibodies.  Illustrated in Figure 3.7, an ELISA test used for HIV diagnostics typically 
involves the addition of patient serum to wells containing immobilized HIV antigens 
(inner core protein p24, envelope protein gp41, and envelope protein gp120, e.g.).  
Ideally, only specific antibodies against these proteins remain in the wells following 
stringent wash procedures.  Bound antibodies are then detected using a secondary anti-
human antibody conjugated to an enzyme such as horse-radish peroxidase, a common 
labeling enzyme which produces a visual signal following the addition of a substrate.68, 69  
A Western blot also involves the incubation of patient anti-serum with viral proteins, and 
the resultant complexes are separated from other serum proteins using gel 
electrophoresis.  Protein bands are then transferred to a nitrocellulose or polymer sheet 
where they are visualized using radiolabeled antibodies.69  IFA employs a similar 
strategy, using whole T cells which have been infected with HIV to react with serum 
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 antibodies rather than protein antigens.  Any antibodies bound to the infected T cells are 
visualized using a fluorescently-labeled secondary anti-human antibody.69  As discussed 
previously, eliminating the need for costly and disruptive labeling strategies in any 
diagnostic approach is ideal, thus highlighting the benefit of applying BSI detection 
strategies to HIV and other diseases. 
.  
 
Figure 3.7 Illustration of the ELISA (indirect) method for detecting specific antibodies. 
 
Like syphilis serology, HIV diagnostics would also benefit from the quantitative 
potential of BSI.  In the early stages of HIV infection, high concentrations of viral core 
protein p24 are secreted and anti-p24 antibodies appear.  The presence of this core 
protein and its antibody response therefore serve as the earliest serological indicators of 
HIV infection.  Levels of this antigen and, subsequently, its antibody, decrease as the 
disease progresses.68  Because of this phenomenon, the quantification of p24 is currently 
being explored as an early detection and/or prognostic tool for HIV infection.  
Furthermore, the measurement of viral load through serological p24 quantification shows 
promise as an effective yet less expensive, less time-consuming, and less labor-intensive 
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 approach than HIV-RNA quantification, the current standard technique for determining 
HIV viral load.70, 71  Utilizing BSI to perform a p24-based diagnostic assay may not only 
offer enhanced sensitivity for both early disease detection and quantification of viral load, 
but may also minimize time, cost, and labor investments associated with these 
measurements.  
 
Experimental procedures 
 Affinity-purified, anti-p24 monoclonal IgG antibody (MAb) was obtained from 
the CDC.  Increasing concentrations of anti-p24 MAb were prepared in PBS, and each 
concentration was mixed with a fixed concentration of p24 antigen, also received directly 
from the CDC, or with PBS to serve as a calibration.  The final concentrations of the anti-
p24 MAb were 0 – 800 nM, and the final p24 antigen concentration was held constant at 
1 nM.  The BSI signal was measured for each sample, and the bulk contributions of the 
MAb were subtracted using the MAb calibration.  The remaining signal, representing the 
antigen-antibody binding, was plotted versus MAb concentration to form a saturation 
isotherm.  The KD value for this binding system was then determined using PrismTM 
software by fitting to a single-site binding model using a square hyperbolic function.  
Clinical serum samples from human patients used for HIV serology experiments 
were provided by the CDC, having been previously classified as positive or negative 
using standard commercial testing methods, such as ELISA.  Serum samples were first 
diluted with 0.1% BSA in PBS and were then mixed with a recombinant protein 
containing the immunodominant gp41 transmembrane regions for 3 subtypes of HIV-1 
class M (denoted rIDRm), developed by the CDC.  Sera samples were reacted with 
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 antigens to a final sera concentration of 1:20 and a final antigen concentration of 4.75 
µg/mL.  For each sample, a control was prepared which consisted of the sera diluted 1:20 
in buffer with no antigen present.  The change in signal, or phase shift, was measured 
between each control serum and the reacted sample (containing the same serum plus 
antigen).  
 
Results and Discussion 
An endpoint saturation binding curve constructed using BSI measurements to 
evaluate the affinity of p24 for the CDC-developed anti-p24 MAb is shown in Figure 3.8.  
From the saturation isotherm plot, the KD for this antigen-antibody pair is calculated to be 
77.1 nM ± 16.7 nM (R2 = 0.99).  Notably, no affinity information was previously known 
for this binding system due to the fact that the antibody was newly synthesized and was 
thus far uncharacterized, highlighting the distinct advantage that BSI can be used to make 
novel KD determinations.  Results suggest that the new MAb does indeed bind with the 
p24 antigen with nanomolar affinity.  Comparing these results with BSI data collected for 
other anti-p24 antibodies may serve as a screening approach for predicting the relative 
performance of these synthetic antibodies in diagnostic assays for HIV. 
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Figure 3.8 BSI signal resulting from the reaction of purified p24 with purified 
recombinant anti-p24 MAb.  Error bars represent the standard deviation of the noise in 
the measurement. 
 
 The reaction of human serum samples, pre-classified according to HIV infection 
status, with newly received rIDRm antigen yielded positive changes for positive samples 
and negative changes for negative samples (Figure 3.9).  These results suggest that a bulk 
negative change in the refractive index of the sera is observed in response to the addition 
of the rIDRm antigen, but a positive RI change is observed if binding occurs.  Although 
very few samples were analyzed and the assay has not yet been optimized, these 
preliminary results show promise for BSI as a reactive serum detector for HIV and other 
diseases.   
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Figure 3.9 BSI signal resulting from the reaction of human serum samples (pre-classified 
as positive or negative with regard to HIV infection) with rIDRm antigen. Error bars 
represent the standard deviation of two trials. 
 
Conclusions 
 The experiments performed using human serum samples demonstrate that BSI 
may be capable of serving as a reactive serum detector in a clinical setting.  Primarily, a 
clear threshold between reactive and nonreactive sera may be determinable for a panel of 
samples using both treponemal and nontreponemal antigens.  Furthermore, the BSI signal 
arising from the binding of antiserum and nontreponemal micellar cardiolipin antigen 
shows a strong correlation with the semi-quantitative RPR test currently in practice.  
Preliminary results of assays interrogating rIDRm reaction with human serum samples 
also show that reactive and nonreactive sera may be distinguished using BSI.  These 
results show promise for utilizing BSI to perform rapid serological tests using a variety of 
molecular probes, offering many possibilities for multiplexed, possibly quantitative 
assays to improve current clinical diagnostics.  Furthermore, BSI may enable the 
characterization and evaluation (i.e., screening) of novel biosensing molecules, such as 
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 the anti-p24 MAb developed by the CDC, to aid in the development of more specific and 
sensitive diagnostic approaches applicable to virtually any assay format.  
39 
 CHAPTER IV 
 
BSI CONFORMATIONAL STUDIES USING REOVIRUS AS A MODEL 
 
Background and Significance 
 
BSI and conformational changes 
 The precise source of the unique binding signal measurable using BSI in free-
solution is currently under investigation.  Because real-time BSI measurements of 
binding signals are observed to level off following equilibrium, the signal must result 
from permanent changes in the refractive index of the interrogated medium, eliminating 
thermal changes as a dominating source of the signal. 56  Furthermore, BSI has 
demonstrated the ability to readily detect the binding of the calcium ion (Ca2+) to 
calmodulin (CaM), a 16 kDa protein, in real-time.  Because of the significant discrepancy 
in size between these two binding species, changes in mass are also insufficient to 
explain the signal source.  However, upon binding with Ca2+, CaM undergoes a marked 
conformational change during which many waters of hydration (>35/CaM) are ejected 
from the compound.72  The ability to monitor this phenomenon has helped to illuminate 
the role of structural and/or molecular dipole changes in producing a signal detectable 
using BSI.  We therefore hypothesize that the BSI signal results from structural changes 
and effects on the molecular dipole of the medium resulting from the interaction of 
binding species.  Such changes probably involve the folding or unfolding of molecules 
and/or changes in waters of hydration upon binding.56.  
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  Here we aim to further explore the ability of BSI to interrogate conformational 
changes within a molecular system, even in the absence of binding.  Specifically, we will 
measure signal differences between reovirus in its native state and following disassembly 
induced by acid exposure and/or proteolytic activity.  These experiments will lend insight 
into BSI’s ability to harness induced conformational changes in molecules as a possible 
diagnostic or signaling strategy.  For example, if two different virus particles generate 
different BSI signal profiles when exposed to the same protease, it may be possible to 
utilize these unique profiles in a diagnostic strategy.  Another potential utility of this 
phenomenon would be to use molecules which are known to undergo characteristic 
structural changes upon exposure to a particular chemical as a signaling moiety.  These 
molecules could be attached to a targeting antibody, potentially enhancing the binding 
signal between the antibody and its target when conformational changes are induced. 
 
Reovirus Disassembly 
 Reovirus is a non-enveloped double-stranded RNA virus which can be isolated 
from human respiratory and enteric tracts but is not associated with significant disease in 
humans.73, 74  However, reovirus has been widely studied as a model for understanding 
the cellular proteolysis of viral proteins, a process which has been implicated in the 
mechanism of infection for influenza virus, rotavirus, HIV, and others.75  Furthermore, 
reovirus has recently shown promise as a novel therapy for the treatment of cancer due to 
its preferential replication in some cancerous cells; phase II clinical studies are currently 
underway.73, 74, 76   
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 Reovirus is comprised of an outer capsid of viral proteins surrounding the “core,” 
or inner capsid, which is a multienzyme complex providing the components necessary for 
viral replication.75, 77  Upon infection of a cell, outer capsid proteins undergo dramatic 
structural changes.  Specifically, the virion first attaches to the cell via outer capsid 
protein σ1, initializing uptake by the cell into acidic compartments known as endosomes 
(i.e., receptor-mediated endocytosis).75, 78  This acidic environment, in combination with 
acid-dependent endosomal proteases, is believed to facilitate the conversion of the 
reovirus from a virion to an intermediate subviral particle (ISVP).75  Once inside the 
cytosol of the cell, the ISVP undergoes further disassembly into the core particle and 
replication occurs.  As shown in Figure 4.1, an ISVP particle lacks the outer coat of σ3, 
an extended form of σ1 is present, and outer capsid proteins µ1 and µ1C (designated 
µ1/C in Figure 4.1) are converted to δ and φ peptides.  In conversion to the core particle, 
σ1, δ, and φ are lost completely75. 
 In collaboration with the Chappell and Dermody labs at Vanderbilt University, the 
intracellular disassembly of reovirus will be studied as a model for A) measuring 
conformational changes using BSI and B) better understanding the viral and host 
determinants that regulate proteolysis in reovirus, which may also be applicable to other 
infectious viruses.  Specifically, the ability of BSI to monitor reovirus conversion from 
virion to ISVP to core particle will be studied using in vitro strategies for generating 
these reovirus products, such as digestion using chymotrypsin or titration with acid.  
While the in vitro digest of reovirus by chymotrypsin is a well-established method for 
facilitating conversion to ISVP and core particles, mimicking the in vivo activity of acid-
dependent proteases cathepsin B and cathepsin L, it is less certain whether a low pH 
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 alone will induce significant conformational changes in the virion.76, 78, 79  If BSI enables 
the successful detection and quantification of conformational changes associated with the 
reovirus disassembly process, this novel biosensing strategy will then be used to assess 
differences in the kinetics of outer-capsid proteolysis between different reovirus mutants.  
These studies will not only lend insight into the physical origins of the BSI signal, 
enabling us to harness conformational changes to design any number of diagnostic 
assays, but may also contribute to an advanced understanding of uncoating processes in 
viral infection. 
 
 
Figure 4.1 Illustration of reovirus as a virion, ISVP, and core particle 
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 Experimental Procedures 
 
Acid titration of dialysis buffer 
A Tris-based buffer (dialysis buffer) was prepared (150 mM NaCl, 15 mM 
MgCl2, 10 mM Tris, pH 7.4).  A fixed volume of increasing concentrations of 
hydrochloric acid (HCl) was added to aliquots of dialysis buffer to achieve final HCl 
concentrations of 0 – 4 mM.  The pH of each sample was then measured and plotted 
versus HCl concentration.   
 
Acid titration of Reovirus 
Purified virions of reovirus type 1 Lang (T1L), dialyzed into a Tris-based buffer 
(150 mM NaCl, 15 mM MgCl2, 10 mM Tris, pH 7.4), were obtained from the Chappell 
laboratory.  T1L was diluted to a concentration of 1.2 x 109 particles/mL using dialysis 
buffer and aliquoted.  A fixed volume of increasing concentrations of HCl was added to 
these aliquots to achieve final HCl concentrations of 0 – 4 mM.  Samples were allowed to 
react for 20 minutes, followed by measurement of the BSI signal for each acid 
concentration point.  Corresponding acid concentrations in dialysis buffer alone were also 
prepared and the BSI signal was measured to serve as a calibration.  The bulk 
contribution of acid was subtracted from the T1L titration measurements using the 
calibration curve, and the resultant BSI signal (due to conformational changes of the 
virions) was plotted versus acid concentration. 
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 Chymotrypsin digest of Reovirus 
Aliquots containing equivalent concentrations of T1L in Tris-based dialysis buffer 
were exposed to Nα-Tosyl-Lys-chloromethylketone (TLCK)-treated chymotrypsin 
(Sigma-Aldrich) for A) 1 hour, and B) 2 hours at 37oC.  At the appropriate time point, the 
reaction was stopped with the enzyme inhibitor phenylmethanesulphonylfluoride 
(PMSF).  Final reagent concentrations were 2 x 1012 particles/mL T1L, 200 µg/mL 
chymotrypsin, and 2 mM PMSF.  The BSI signal was measured for each time point 
immediately following the addition of PMSF.  A solution of 2 x 1012 particles/mL T1L 
alone (replacing chymotrypsin and PMSF with equivalent volumes of dialysis buffer) 
was also prepared to serve as the “0 hour” time point.  In addition, solutions of 200 
µg/mL chymotrypsin and 2 mM PMSF were prepared and the BSI signal was measured 
to determine the bulk refractive index contributions of these reagents.  Bulk contributions 
of PMSF and chymotrypsin were subtracted from the T1L digest measurements at 1 and 
2 hours.  The resultant BSI signal (due solely to conformational changes of the virions) 
was zeroed according to the bulk signal of the “0 hour” sample (representing no 
conformational change) and was plotted. 
 
SDS-PAGE analysis of digest results 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed on products generated via chymotrypsin digest of reovirus. Specifically, 4 x 
1010 viral particles of each sample were dissolved in 6X SDS sample buffer (0.35 M Tris, 
pH 6.8, 30% glycerol, 10% SDS, 0.6 M dithiothreitol).  Samples were heated to 98oC for 
5 minutes and loaded onto a 4-20% gradient Tris-HCl gel (Bio-Rad).  Proteins were 
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 resolved by electrophoresis in Laemmli buffer (0.025 M Tris, 0.2 M Glycine, 0.1% SDS) 
at a constant voltage of 120V for 1.5 hours.  The gel was fixed and stained using colloidal 
blue (Invitrogen) and visualized using and Odyssey infra-red imager (Li-Cor.)  
 
Results and Discussion 
Figure 4.2 shows the pH values for a range of acid concentrations in dialysis 
buffer.  These experiments were performed to determine the acid concentration yielding 
the desired pH range to mimic the endosomal environment in this particular buffer 
system, providing insight into the approximate acid concentration where conformational 
changes may be expected to begin when titrating reovirus with HCl.  Based on these 
results and the assumption that reovirus disassembly occurs in endosomes (pH range of 
5-6), conformational changes (if occurring at all) would be expected to be induced at acid 
concentrations above 2 mM HCl in dialysis buffer.  
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Figure 4.2 pH values for the various acid concentrations (final) in dialysis buffer. Error 
bars represent the standard deviation of triplicate determinations. 
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The results of the acid titration of reovirus T1L strain at a concentration of 1.2 x 
109 particles/mL are shown in Figure 4.3.  Although the measurements are very noisy 
(error bars represent 3 trials of both the acid calibration curve and the T1L titration), a 
sharp downward signal is observed at an acid concentration of approximately 2.2 mM, 
corresponding to a pH of approximately 6.15.  Notably, a negative signal is not 
unexpected as conformational changes may result in either a positive or negative change 
in refractive index.  Although these preliminary results suggest that reovirus may be 
undergoing conformational changes in the presence of acid at concentrations resembling 
those of endosomes, more studies must be performed to confirm the relevance of this 
data.  In particular, this assay may benefit greatly from an increase in reovirus 
concentration and/or an increase in incubation time, supported by the observation that the 
exposure of 2 x 1012 reovirus particles/mL to chymotrypsin for 1-2 hours produces a 
distinguishable but not excessively large signal in Figure 4.4.A.  Presumably, any 
conformational changes owed to pH alone would be less significant than those induced 
by protease digestion.  Therefore, the concentration of T1L necessary to observe acid-
induced changes in conformation is likely to be greater than or equal to that necessary to 
observe protease-induced conformational changes. 
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Figure 4.3 BSI signal resulting from the reaction of reovirus T1L strain (1.2 x 109 
particles/mL) with acid at various concentrations.  Error bars represent the combined 
standard deviations of 3 trials of both the acid calibration curve and the T1L titration.  
 
The results of the chymotrypsin digest of T1L are shown in Figure 4.4.A.  
Reovirus concentration was increased to 2 x 1012 reovirus particles/mL in order to 
provide sufficient product for protein visualization on an SDS-PAGE gel Figure 4.4.B. 
These results demonstrate that a negative BSI signal results from T1L disassembly, an 
observation that corroborates the suspicion that acid titration may initiate degradation (a 
negative trend, albeit far less pronounced, is also seen in Figure 4.3).  A marked change 
in BSI signal is observed upon reovirus exposure to chymotrypsin for 1 hour, and this 
signal continues to increase in magnitude as supported by what is seen on gel.  Gel results 
taken of these same samples following digestion indicate that after a 1 hour exposure to 
chymotrypsin, most of the T1L particles have converted from the virion stage to the ISVP 
stage.  This conversion is evidenced by the near disappearance of µ1 and σ3, and the 
appearance of δ (see figure 4.1 for structural significance of these bands).  While the aim 
of the 2-hour exposure to chymotrypsin was to achieve conversion from ISVP to core 
particle, the gel results show that this additional change did not occur. However, the 
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 further disappearance of µ1, the complete disappearance of σ3, and the appearance of a 
more prominent δ band show that the majority of virions remaining after the 1 hour 
digestion were converted to ISVPs after 2 hours.  Therefore, the observation that the BSI 
signal change from 1 to 2 hours is clear, yet less dramatic than the signal change from 0 
to 1 hour, is not surprising.   
Although further studies must be performed to understand how the BSI signal 
might change if the conversion from ISVP to core particle is achieved, it is suspected that 
the signal may plummet markedly as observed for the conversion of virion to ISVP.  
Specifically, Coombs suggests that a 3-hour chymotrypsin digest using the same assay 
conditions may achieve the full conversion of virion to core particle.77  Furthermore, a 
wealth of information may be gained from a real-time analysis of T1L digestion over the 
course of several hours.  Such an experiment may assist in more precisely identifying the 
BSI signal change resulting from individual protein alterations of T1L during 
disassembly by enabling the construction of a real-time kinetics profile of these reactions.   
Once BSI profiles for the proteolytic conversion of the T1L wild-type to its ISVP 
and core particle stages are well-established, other strains, such as Type-3 Dearing 
(T3D), and mutants of these strains will be interrogated in the same manner and 
compared to T1L wild-type.  Specifically, the Dermody lab studies reovirus mutants 
which demonstrate differences in the time course of proteolytic conversion.  These 
experiments will not only investigate the ability of BSI to distinguish pathogens based on 
differences in induced conformational changes, but may also lend insight into the kinetics 
of viral capsid proteolysis for these different reovirus mutants and strains. 
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Figure 4.4 Chymotrypsin digest of reovirus T1L strain as evidenced by A) comparison of 
the BSI signal of T1L products before and after exposure to chymotrypsin (error bars 
represent 3 trials) and B) SDS-Page gel of these same products. Note: SDS-PAGE gel 
performed by Joshua Doyle (Dermody lab). 
 
 
Conclusions 
 Although these experiments are in the preliminary stages, the results help bolster 
the suspicion that the source of the BSI signal is related to conformational changes in 
molecules.  In particular, the detection of a marked difference between virion and ISVP 
(and between these stages and a more complete conversion to ISVP) suggests that BSI 
can detect viral degradation/conversion.  These findings may enable the harnessing of 
induced conformational changes for optimized label-free signaling in diagnostic assays; 
specifically, environmental conditions such as pH, ionic strength, and/or the presence of 
proteases may be used strategically to determine unique profiles for specific analytes, 
such as a particular virus strain.  Furthermore, molecules which generate a significant 
BSI signal in response to these conditions may be attached to probes as signaling 
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 moieties, serving to enhance the BSI measurement of more elusive analytes that do not 
produce large conformational changes on their own. 
 In addition to the potential implications for BSI biosensing, these findings also 
imply the possibility that a low pH alone may have a role in the conformational changes 
occurring upon reovirus entry into the cell, rather than serving strictly to provide a 
functional environment for acid-dependent proteases (Figure 4.3).  However, more 
studies are necessary to support this theory.  Perhaps more importantly, Figure 4.4 shows 
that BSI may be a valuable tool for aiding in the characterization of reovirus conversion 
kinetics, and potential experiments comparing different reovirus strains and mutants may 
lend insight into important kinetic differences in the proteolytic disassembly of these 
species.  
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 CHAPTER V 
 
SYNOPSIS AND CONCLUSIONS 
 
As shown in Chapters I and II, interferometry continues to be a powerful 
approach to biosensing.  While each method discussed or reported elsewhere has 
advantages, it appears that BSI is somewhat unique, enabling previously impossible 
molecular interactions studies.  In particular, BSI enables both free-solution and surface-
immobilized assay formats, allowing for enormous flexibility in quantifying binding 
affinities, determining labeling perturbations, screening for binding, and detecting the 
presence of analytes in diagnostic applications.   
The potential application of BSI as a diagnostic tool is demonstrated in Chapter 
III, highlighting that BSI can detect relevant antibody analytes against a background of 
human serum using antigen probes.  These results suggest that BSI may be used as a 
reactive serum detector for syphilis, HIV, and virtually any other disease causing a 
significant and specific immune response.  Furthermore, the correlation of BSI signal 
with titer strength in nontreponemal syphilis serology assays using clinical samples 
demonstrates quantitative potential of BSI in diagnostic applications.  While additional 
studies are necessary to evaluate the performance of BSI in a point-of-care setting, these 
preliminary studies and the knowledge that BSI is a simple, rapid optical method 
compatible with microfluidics show promise for clinical applications of this technique. 
The source of the BSI signal is explored in Chapter IV in preliminary studies 
using reovirus as a model for measuring induced, specific conformational changes.  
52 
 Results suggest that BSI does indeed measure conformational changes, even in the 
absence of binding, such as the conversion of reovirus virions into ISVP particles.  As we 
continue efforts to better understand how these conformational changes contribute to the 
BSI signal, we aim to harness induced conformational changes to diagnostic and other 
applications.  Furthermore, expounding upon these studies may provide valuable kinetic 
information regarding the mechanism of reovirus entry into cells, lending insight into 
processes which are common among many clinically relevant viral infections.  
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